As traditional compound utilization and cost continue to decline, high impact therapeutic categories are emerging to take their place. In 2018, compound kits and combo packs each represented less than 1% of total prescriptions and drug costs. However, their presence is of growing concern due to the lack of evidence supporting their use and packaging strategies that are associated with exorbitant pricing. These and other challenges call for careful oversight that includes identification, clinical review and intervention, and/or recommendation of therapeutic alternatives where appropriate to help control inappropriate utilization and spend. Watch the video blog to learn more.
More stories
Workers' Comp
Case Study
How Enlyte’s Customized Telephonic Case Management Approach Boosted Efficiency and Savings for a Major Carrier
Workers' Comp
Article
Remote Telephonic Ergonomics Assessments
We put years of experience in medical and disability management into action by assisting employers, carriers, and third-party administrators with r
Workers' Comp
Article
Specialty Solutions Spotlight: Expert Care Coordination for Catastrophic Claims
How can working with a specialty solutions provider ensure the best possible results on a catastrophic injury claim? Workers’ compensatio
Workers' Comp
Podcast
Gauging the Impact of High-Impact Drugs in Workers’ Comp
Enterprise Mobility
In the News
Collision Engineering Program Receives Software Donation from Mitchell
Mitchell
News Release
Mitchell Introduces Enhanced Solution for Vehicle Owner Communication and Engagement
The company’s latest technology, Mitchell ServiceLink powered by UpdatePromise, integrates repair status updates into Mitchell Connect and all